



an Open Access Journal by MDPI

State-of-the-Art Neurobiology and Neurologic Disease in Portugal

Guest Editors:

Dr. Cristina Carvalho

Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517, Coimbra, Portugal

Dr. Sónia Catarina Correia

Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal

Dr. Susana Cardoso

Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal

Deadline for manuscript submissions:

closed (30 April 2023)

Message from the Guest Editors

Portugal has a long reputation in the study of neurological and behavioral disorders. Going back to the pioneer work of Egas Moniz, the developer of cerebral angiography and one of the founders of modern psychosurgery, to the renowned neuroscientist António Damásio, who pursued the understanding of the boundaries between the mind and the brain, currently, there are several Portuguese physicians and researchers committed to improving the neurocognitive and neuropsychological profile of the individual in different contexts and phases of life.

Importantly, the natural history of neurobiology and neurologic diseases in Portugal is marked by the occurrence of two rare hereditary disorders, the transthyretin familial amyloid polyneuropathy with endemic populations predominantly in the north of Portugal and Machado–Joseph disease with a high prevalence in the islands of Azores.

This Special Issue is intended to honor the pioneering achievements made by Portuguese physicians in the neurology field and to present the scientific developments in epidemiology, diagnosis, and treatment of neurologic diseases in Portugal.



mdpi.com/si/93120

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI